Archived explainer. For the current picture see today's AVBP page.
ARRIVENT BIOPHARMA I (AVBP) is up +11.93% in the latest session. Our newswire has captured 11 stories on AVBP across 5 sources in the last 36 hours, with AI sentiment reading bearish (avg 29/100).
ArriVent BioPharma stock rose 11.93% to $16.89 on Wednesday, marking a sharp rebound after a severe sell-off. The primary driver of the move appears to be a stabilization in trading following the disclosure that the company’s Phase 3 FURVENT trial for firmonertinib missed its primary endpoint. This news had previously triggered a significant decline, with the stock falling as much as 56.7% before the opening bell and hitting a low of $12.09.
ArriVent BioPharma announced that its Phase 3 FURVENT trial of firmonertinib failed to meet its primary endpoint, specifically the BICR PFS metric, despite showing encouraging investigator-assessed efficacy. This result led to a rapid reassessment of the company’s investment case, with analysts issuing downgrades and lower price targets. Guggenheim lowered its price target to $18 from $45, while Citi cut its target to $20 from $40. Clear Street reduced its target to $22 from $47, and Jones lowered its target to $22 from $45. BTIG also cut its price target, though the specific new figure was not detailed in the immediate release, noting the trial results as the catalyst.
Legal scrutiny has also increased in the wake of the trial failure. Law firms including SueWallSt and Levi & Korsinsky have notified investors of potential securities claims and pending investigations into ArriVent BioPharma. These notices highlight the timing of the trial miss, which occurred just five months after the company launched a $250 million at-the-market stock offering. The combination of clinical disappointment and legal inquiries created substantial volatility, pushing the stock to a 52-week low of $12.09 before the recent intraday recovery.
The stock’s recent performance reflects extreme volatility, with the share price down 42.4% over the last eight sessions, moving from $29.30 to $16.89. The 52-week range for AVBP is $11.36 to $35.83, and the company recently printed two fresh 52-week lows on October 7, 2026. Fundamentals indicate a market cap of $1.4 billion, with the company remaining unprofitable and reporting a trailing twelve-month EPS of negative $3.70. The stock exhibits high volatility relative to the broader market, with a beta of 1.35.
Investors are monitoring the extent of the legal investigations and any further analyst commentary regarding the long-term viability of the firmonertinib program. The recent price target cuts suggest a significant reset in valuation expectations, and the stock’s ability to hold its current level above the recent lows will be a key indicator of sentiment recovery.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AVBP was down 56.7% before the opening bell and traded as low as $12.09 after ArriVent disclosed that its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway. NEW YORK, Oct. 7, 2026 /PRNewswire/ --...
BTIG cuts ArriVent BioPharma stock price target on trial results
AVBP shareholders are holding stock near a $12.09 52-week low after the Phase 3 FURVENT trial missed its primary endpoint, just five months after ArriVent launched a $250 million at-the-market stock offering. NEW YORK, Oct. 6, 2026 /PRNewswire/ -- A 56.7% premarket plunge hit AVBP...
ArriVent's Firmonertinib failed its primary BICR PFS endpoint despite encouraging investigator-assessed efficacy, weakening the outlook. Read more on AVBP.
More on AVBP: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AVBP move explainers: 2026-10-08 · 2026-10-07 · 2026-10-06